Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03810313 · ClinicalTrials.gov registry record · Phase 3
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 493
- Enrollment target
NCT03810313 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 493 participants.
The verdict
NCT03810313, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 493 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
Interventions
- OTHER Sham injection
- DRUG Brolucizumab 6 mg
- DRUG Aflibercept 2 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 493 participants |
| Start Date | 2019-07-03 |
| Est. Completion | 2021-07-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03810313
The ClinicalTrials.gov registry entry for NCT03810313 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 493 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sham injection is the first listed.
NCT03810313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03810313 about?
NCT03810313 is a clinical study titled "Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion". The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).
What is the current status of trial NCT03810313?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 493 participants. The study started on 2019-07-03. Estimated completion is 2021-07-26.
What interventions are being tested in trial NCT03810313?
The interventions under investigation include: Sham injection (OTHER), Brolucizumab 6 mg (DRUG), Aflibercept 2 mg (DRUG).
Who is sponsoring clinical trial NCT03810313?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.